Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

65.47 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Aug 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
92 93 Next >
News headline image
Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now? ↗
Whichever one you choose, you'll need patience before you can see solid returns. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
News headline image
Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks ↗
Bristol Myers Squibb has an attractive 4.4% yield, and its 16x P/E is below the pharma average of 24x. 
Via The Motley Fool
Topics Intellectual Property
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma
From Bristol Myers Squibb
Via Business Wire
News headline image
Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q1
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
News headline image
1 Surging Stock with Promising Prospects and 2 We Ignore
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab... 
Via StockStory
News headline image
Looking to Buy Bristol Myers Squibb Stock on the Dip? Read This First. ↗
The numbers don't tell the full story with this big pharma stock. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline
From Bristol Myers Squibb
Via Business Wire
News headline image
The Most Undervalued Healthcare Stock in the S&P 500 Right Now ↗
The market appears to be short-sighted. 
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
1 Profitable Stock to Keep an Eye On and 2 We Brush Off
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
Topics Energy
News headline image
Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations
From Bristol Myers Squibb
Via Business Wire
News headline image
3 High-Yielding Dividend Stocks Trading at Dirt Cheap Valuations ↗
These stocks are facing adversity, but with high yields and cheap valuations, investors may be compelled to take a chance on them. 
Via The Motley Fool
News headline image
10 Years Later: 5 Winners in a Thinking World ↗
What happens when you actually do the thing most investors only talk about and hold stocks for a full decade? 
Via The Motley Fool
News headline image
2 Large-Cap Stocks to Consider Right Now and 1 We Turn Down
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit... 
Via StockStory
News headline image
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees
From Pacira BioSciences
Via GlobeNewswire
News headline image
Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q1 Earnings?
Bristol-Myers Squibb has had an impressive run over the past six months as its shares have beaten the S&P 500 by 5.7%. The stock now trades at $55.77, markin... 
Via StockStory
Topics Stocks
News headline image
Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors. ↗
This may be an excellent deal for those focused on the long game. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol Myers Squibb Touts Pipeline Gains as Shareholders Back Board at Annual Meeting ↗
Bristol Myers Squibb (NYSE:BMY) used its 2026 annual meeting of shareholders to highlight progress in its growth portfolio, pipeline development, balance sheet management and cost-saving initiatives,... 
Via MarketBeat
News headline image
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol-Myers Squibb’s Q1 Earnings Call: Our Top 5 Analyst Questions
Bristol-Myers Squibb’s first quarter results were notably shaped by ongoing momentum in its growth portfolio and steady execution across key marketed product... 
Via StockStory
Topics Earnings
News headline image
Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
1 Healthcare Stock with Competitive Advantages and 2 Facing Challenges
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged... 
Via StockStory
News headline image
Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026™
From Bristol Myers Squibb
Via Business Wire
News headline image
BMY Q1 Deep Dive: Growth Portfolio, Pipeline Milestones, and Anticipated Late-Stage Readouts
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q1 CY2026, with sales up 2.6% year on year to $11.49 bill... 
Via StockStory
News headline image
Why Bristol Myers Squibb Stock Rocked the Market Today ↗
It scored crushing beats on both revenue and profitability in its first quarter. 
Via The Motley Fool
News headline image
Bristol Myers (BMY) Q1 2026 Earnings Transcript ↗
Bristol Myers (BMY) Q1 2026 Earnings Transcript 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
92 93 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.